Paulson & Co

#### I. Institutional Overview: The Psychological Portrait and Strategic Evolution of Paulson & Co. The 13F filing for the fourth quarter of 2025 provides a transparent window into the investment mind of John Paulson and his firm, Paulson & Co. To understand the current state of this portfolio, one must first understand the pedigree of the man behind it. John Paulson is a figure etched into the annals of Wall Street history, primarily for "The Greatest Trade Ever," where he successfully bet against the subprime mortgage market in 2007, netting billions for his investors and himself. However, the Paulson of 2025 is not the same as the Paulson of 2007. The current portfolio reflects a transition from a massive, multi-strategy hedge fund powerhouse to a more streamlined, highly concentrated, and conviction-driven investment vehicle, often resembling a family office in its risk appetite and long-term horizon. As of December 31, 2025, the reported value of the Paulson & Co. portfolio stands at approximately **$3.26 billion**. While this is a significant sum, it represents a stabilized scale compared to the peak years of the firm. The most striking metric in this report is the **number of stocks: 9**. This is an extreme level of concentration that is rarely seen in institutional management of this scale. In the world of institutional investing, a portfolio with fewer than 30 stocks is considered "concentrated." A portfolio with only 9 stocks is "hyper-concentrated." This suggests a psychological profile of an investor who has moved away from broad market exposure and instead focuses on a handful of "high-conviction" bets where he believes he has a significant informational or analytical edge. This concentration implies that Paulson is not interested in "closet indexing" or smoothing out volatility through diversification. Instead, he is practicing a form of "punch card" investing—the idea that an investor should only make a few great investments in their lifetime. Each of these 9 positions carries immense weight, meaning that the success or failure of a single company, such as **MDGL (Madrigal Pharmaceuticals)** or **PPTA (Perpetua Resources)**, will have a disproportionate impact on the total fund performance. This is the hallmark of an investor who prioritizes "absolute return" over "relative return." Paulson is not trying to beat the S&P 500 by 1% with a diversified basket; he is looking for idiosyncratic wins in specific sectors. The psychological portrait revealed here is one of **patient, contrarian, and event-driven conviction**. Many of the holdings, such as **NovaGold (NG)** and **International Tower Hill Mines (THM)**, have been in the portfolio for over a decade. This indicates a "permanent capital" mindset. Paulson is willing to wait years, or even decades, for a thesis to play out—whether that thesis is a surge in gold prices, a breakthrough in biotech, or a corporate restructuring. He is not a "momentum chaser." In fact, his willingness to hold onto **Bausch Health (BHC)** despite a significant decline in value (-72.73% PnL) suggests a "deep value" or "distressed debt" mentality, where he believes the market is fundamentally mispricing the long-term recovery potential of the asset. Furthermore, the scale of the portfolio combined with the low turnover (only one new buy and two exits this quarter) suggests a "fortress" strategy. Paulson has built a portfolio of "ballast stones"—large, heavy positions that he intends to ride through market cycles. The expansion or contraction of the portfolio value in this quarter seems to be driven more by the price appreciation of core assets like Madrigal Pharmaceuticals and Perpetua Resources rather than aggressive new capital deployment. In summary, Paulson & Co. in Q4 2025 is a **specialized, high-conviction vehicle focused on specialized materials and healthcare, characterized by extreme patience and a total disregard for traditional diversification.** #### II. Sector Allocation Analysis: Macro Signals and Track Selection The sector allocation of Paulson & Co. is perhaps the most lopsided of any major institutional investor, revealing a very specific macro-economic worldview. By analyzing the weights across different industries, we can infer Paulson’s judgments on inflation, the biotech innovation cycle, and the global demand for strategic minerals. | Sector | Weight (%) | Trend | | :--- | :--- | :--- | | Healthcare | 46.09 | Dominant Core | | Materials | 39.87 | Strategic Hedge | | Financials | 11.16 | Niche Allocation | | Technology | 2.08 | Emerging Interest | | Communication Services | 0.81 | Residual Position | | Industrials | 0 | Complete Exit | **1. Hyper-Concentration and the "Two-Pillar" Strategy** The most immediate observation is that the top two sectors—**Healthcare and Materials**—account for a staggering **85.96%** of the total portfolio. If we include Financials, the top three sectors represent **97.12%**. This is not a diversified portfolio; it is a "Two-Pillar" strategy. Paulson has essentially bet half the house on the success of specific medical breakthroughs and the other half on the value of the earth's crust (gold and strategic minerals). This concentration indicates a belief that these two sectors offer the best risk-adjusted returns in the current macro environment, likely due to their "uncorrelated" nature relative to the broader tech-heavy indices. **2. Healthcare: The Search for Idiosyncratic Alpha (46.09%)** Healthcare is the largest allocation, but it is not "defensive" healthcare in the traditional sense (like Johnson & Johnson or UnitedHealth). Instead, it is dominated by **Madrigal Pharmaceuticals (MDGL)** and **Bausch Health (BHC)**. This suggests Paulson is looking for "idiosyncratic alpha"—gains driven by specific company events rather than broad industry trends. Madrigal represents a bet on a revolutionary treatment for NASH (non-alcoholic steatohepatitis), while Bausch Health is a complex turnaround and deleveraging play. By allocating nearly half of his capital here, Paulson is signaling that he believes the "innovation curve" in biotech and the "valuation recovery" in distressed pharma are the most potent drivers of wealth creation today. **3. Materials: The Inflation and Geopolitical Hedge (39.87%)** The massive weight in Materials is a classic Paulson move. Historically, Paulson has been a vocal proponent of gold as a hedge against currency debasement and inflation. The holdings in **Perpetua Resources (PPTA)**, **NovaGold (NG)**, **Agnico Eagle Mines (AEM)**, and **International Tower Hill Mines (THM)** confirm that his "Gold Bug" thesis remains a core part of his investment identity. However, there is a modern twist: **Perpetua Resources** is not just a gold play; it is also a play on **Antimony**, a critical mineral for the defense industry and clean energy storage. This suggests Paulson is pivoting from "pure gold" to "strategic materials" that have geopolitical importance. The high concentration in Materials indicates a cautious outlook on the long-term stability of fiat currencies and an optimistic view on the "hard asset" cycle. **4. Sector Rotation: The Exit from Industrials** A significant signal this quarter is the reduction of **Industrials to 0%** following the exit from **Honeywell (HON)**. Honeywell is a diversified industrial giant, often seen as a proxy for the broader economy. Paulson’s decision to exit this position entirely suggests a move away from "macro-sensitive" or "cyclical" stocks toward more "event-specific" stocks. He is trading the steady, diversified cash flows of an industrial conglomerate for the high-variance, high-reward potential of biotech and mining. This could be interpreted as a judgment that the broad industrial sector is fully valued, or that the "alpha" is now found only in highly specialized niches. **5. Macroeconomic Inference: Preparing for a "Bifurcated" Economy** From this allocation, we can infer Paulson's macro view: * **Inflation/Currency Risk**: High (hence the 40% in Materials). * **Economic Growth**: Uncertain (hence the exit from Industrials). * **Innovation Premium**: High (hence the 46% in Healthcare/Biotech). Paulson seems to be ignoring the "middle" of the market—the consumer discretionary, retail, and traditional tech sectors—to focus on the "extremes": the fundamental value of gold and the speculative value of life-saving medicine. This is a "Barbell Strategy" designed to perform in an environment where traditional equity correlations might break down. #### III. Top 10 Holdings Deep Dive: Portfolio Cornerstone and Core Logic Bec ---